SAN FRANCISCO—Patients with overactive bladder (OAB) who respond well to 12 weeks therapy with a percutaneous tibial nerve stimulation (PTNS) device are likely to have sustained improvement at 12 ...
MINNEAPOLIS, Sept. 26, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding ...
This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. The procedure is ideal in this population because it is minimally invasive and highly efficacious The ...
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and ...
Uroplasty UPI, a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results